Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies

NCT01399840 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01399840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01399840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
May 31, 2014
Enrollment
33 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, myelodysplastic syndrome